A Phase 2 interventional study of pembrolizumab and Acalabrutinib in Squamous Cell Carcinoma of the Head and Neck, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca — 4 open to participants now, 6 under way, 2 of them phase 3. Squamous Cell Carcinoma of Head and Neck · AstraZeneca.
Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 2, and was the 6th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →4 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 9 more countries
Ages 18+
AstraZeneca · Sites in United States, Austria, Belgium and 20 more countries
Ages 18–130
AstraZeneca · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 4
First in 2003; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 78 across the 21 interventional studies, 412 across the 1 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
1 of the studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in subjects with advanced head and neck squamous cell carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pembrolizumab
Drug: pembrolizumab
acalabrutinib in combination with pembrolizumab
Drug: pembrolizumab · Drug: Acalabrutinib
Also known as: Keytruda
Also known as: ACP-196
Number of Participants With Overall Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: 52 weeks
| Milestone | Mono Therapy of Pembrolizumab Arm 1 | Combo Therapy Acalabrutinib + Pembrolizumab Arm 2 |
|---|---|---|
| Started | 39 | 39 |
| Enrolled | 39 | 39 |
| Received study medication | 39 | 37 |
| Discontinue study | 39 | 39 |
| Completed | 0 | 0 |
| Not completed | 39 | 39 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Mono Therapy Arm - Pembrolizumab | Combo Therapy Arm - Acalabrutinib and Pembrolizumab |
|---|---|---|
| Number of Participants With Overall Response | 7 | 5 |
Collected over Safety Analysis tracked from 0 day to 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 - Pembrolizumab | 26/39 (66.7%) | 12/39 (30.8%) | 39/39 (100%) |
| Arm 2 - Acalabrutinib + Pembrolizumab | 23/37 (62.2%) | 25/37 (67.6%) | 37/37 (100%) |
| Event | Arm 1 - Pembrolizumab | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/39 | 4/37 |
| Acute Kidney InjuryRenal and urinary disorders | 0/39 | 3/37 |
| PneumoniaInfections and infestations | 2/39 | 3/37 |
| Tumour HeaorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/39 | 0/37 |
| PyrexiaGeneral disorders | 0/39 | 2/37 |
| UrosepsisInfections and infestations | 0/39 | 2/37 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/39 | 2/37 |
| SepsisInfections and infestations | 0/39 | 2/37 |
| Cardiac Failure CongestiveCardiac disorders | 2/39 | 0/37 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 2/39 | 0/37 |
| Event | Arm 1 - Pembrolizumab | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| FatigueGeneral disorders | 20/39 | 14/37 |
| AnaemiaBlood and lymphatic system disorders | 2/39 | 12/37 |
| DiarrheaGastrointestinal disorders | 6/39 | 11/37 |
| Decreased AppetiteMetabolism and nutrition disorders | 7/39 | 11/37 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/39 | 11/37 |
| DehydrationMetabolism and nutrition disorders | 2/39 | 10/37 |
| Oedema PeripheralGeneral disorders | 4/39 | 9/37 |
| NauseaGastrointestinal disorders | 4/39 | 9/37 |
| Weight DecreasedInvestigations | 5/39 | 9/37 |
| PyrexiaGeneral disorders | 5/39 | 8/37 |
| Age, Continuous(Years) | Mono Therapy Arm - Pembrolizumab | Combo Therapy Arm - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Mean | 62.1 ± 10.45 | 61.4 ± 11.12 | 61.8 ± 10.71 |
| Sex: Female, Male(Participants) | Mono Therapy Arm - Pembrolizumab | Combo Therapy Arm - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 34 | 35 | 69 |
| Ethnicity (NIH/OMB)(Participants) | Mono Therapy Arm - Pembrolizumab | Combo Therapy Arm - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 35 | 35 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Mono Therapy Arm - Pembrolizumab | Combo Therapy Arm - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 6 | 6 |
| White | 37 | 29 | 66 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Mono Therapy Arm - Pembrolizumab | Combo Therapy Arm - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| United States | 39 | 37 | 76 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2015 to primary completion in May 2018, 36 months.
Results were first posted in Sep 2019, 1 year 4 months after primary completion.
Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 36 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Squamous Cell Carcinoma of Head and Neck →